Marina Sierra-Boada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina Sierra-Boada has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Elisa Nuez-Zaragoza
Clinical Laboratory Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain
3 shared publications - Indira Bhambi-Blanco
Clinical Laboratory Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain
3 shared publications - Isabel Aparicio-Calvente
Clinical Laboratory Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain
3 shared publications - Joan Carles Ferreres
Pathology Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain
3 shared publications - Laia Mas-Maresma
Internal Medicine Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain
3 shared publications - Luis Frisancho
Digestive System Department Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT‐CERCA), Universitat Autònoma de Barcelona Sabadell Barcelona Spain
3 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (6) , e71955
A Three‐Step Diagnostic Strategy for Malignant Pleural Effusions
New diagnostic tools, such as high fluorescence cells (HFc) and tumor markers (TMs), have emerged in the quest to accurately diagnose malignant pleural effusion (MPE). This study evaluated the diagnostic performance of the HFc and TMs combination. Hospitalized patients with pleural effusion were recruited at Parc Taulí University Hospital in Sabadell (Spain). Pleural fluid (PF) and serum samples were collected and analyzed in the Clinical Laboratory, and PF samples were sent to the Pathology Department for cytological examination. PF cell counts were determined using an XN‐10 analyzer (Sysmex, Kobe, Japan); TMs (CEA, CA 19.9, CA 15.3, CA 72.4, and CYFRA 21.1) were assessed using Cobas e801 (Roche Diagnostics, Mannheim, Germany). An MPE diagnosis was made based on positive cytology and/or positive pleural biopsy. A diagnostic algorithm was developed to detect MPE starting with an initial HFc screening, followed by TM determination with specific cutoffs depending on fluid type. The study included 300 pleural effusions from 209 patients. The algorithm had a sensitivity of 68% and a negative predictive value of 93%; its specificity and positive predictive value were both 100%. When combined with cytology, the sensitivity of the algorithm increased to 85%, and its negative predictive value to 96%. Our algorithm exhibited promising diagnostic performance and could serve as a non‐invasive tool for MPE detection. HFc screening helps identify potential MPE cases, and TM assessment, with its high specificity, contributes to MPE confirmation. Furthermore, establishing different TM cutoffs based on fluid type increases sensitivity without reducing specificity by introducing false positives.
- 16 June 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (6) , e71955
Open AccessA Three‐Step Diagnostic Strategy for Malignant Pleural Effusions
New diagnostic tools, such as high fluorescence cells (HFc) and tumor markers (TMs), have emerged in the quest to accurately diagnose malignant pleural effusion (MPE). This study evaluated the diagnostic performance of the HFc and TMs combination. Hospitalized patients with pleural effusion were recruited at Parc Taulí University Hospital in Sabadell (Spain). Pleural fluid (PF) and serum samples were collected and analyzed in the Clinical Laboratory, and PF samples were sent to the Pathology Department for cytological examination. PF cell counts were determined using an XN‐10 analyzer (Sysmex, Kobe, Japan); TMs (CEA, CA 19.9, CA 15.3, CA 72.4, and CYFRA 21.1) were assessed using Cobas e801 (Roche Diagnostics, Mannheim, Germany). An MPE diagnosis was made based on positive cytology and/or positive pleural biopsy. A diagnostic algorithm was developed to detect MPE starting with an initial HFc screening, followed by TM determination with specific cutoffs depending on fluid type. The study included 300 pleural effusions from 209 patients. The algorithm had a sensitivity of 68% and a negative predictive value of 93%; its specificity and positive predictive value were both 100%. When combined with cytology, the sensitivity of the algorithm increased to 85%, and its negative predictive value to 96%. Our algorithm exhibited promising diagnostic performance and could serve as a non‐invasive tool for MPE detection. HFc screening helps identify potential MPE cases, and TM assessment, with its high specificity, contributes to MPE confirmation. Furthermore, establishing different TM cutoffs based on fluid type increases sensitivity without reducing specificity by introducing false positives.
- Open Access
- 7 April 2026
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 7 (2) , 105-115
Determination of HE4 in pleural fluid and ratio: considerations and diagnostic performance for malignant pleural effusion
Objectives: The objectives of this study included assessing the diagnostic performance of HE4 in malignant pleural effusions (MPEs) and identifying the benign etiologies associated with higher HE4 concentrations. Methods: The study involved patients with pleural effusion (PE) treated at Part Taulí University Hospital. PE and serum samples were collected and analyzed. Diagnosis of MPE was established by the presence of a positive cytology and/or positive pleural biopsy. HE4 concentrations in LP and serum – among other parameters – were measured on an ECLIA-Cobas e801 (Roche Diagnostics) analyzer. Subsequently, pleural fluid to serum HE4 ratio (PF/serum HE4 ratio) was calculated. Patients were assigned to different groups according to final diagnosis, transudate vs. exudate, MPE etiology and estimated glomerular filtration rate (eGFR). An evaluation was performed of the diagnostic performance of HE4 for MPE. Results: A total of 253 PF and serum samples were included. In patients with benign pleural effusion (BPE), transudates contained higher levels of HE4, as compared to exudates. The highest PF-HE4 concentrations and ratios were observed in MPEs, especially in patients with non-small cell lung cancer + ovarian cancer. The cut-off values established showed a sensitivity of 16.7 % (PF-HE4) and 12.1 % (ratio), with a 100 % specificity, respectively. Following cut-off adjustment, higher sensitivity values were observed in patients with an eGFR ≥ 30 mL/min/1.73 m 2 . Conclusions: Elevated HE4 concentrations may support MPE diagnosis and predict histology. Transudates contain elevated levels of HE4 and lower PF/serum-HE4 ratios. In the investigation of solid neoplasms, different serum HE4 cut-off values should be used for patients with PE, heart failure, cirrhosis or renal insufficiency.
- 7 April 2026
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 7 (2) , 105-115
Open AccessDetermination of HE4 in pleural fluid and ratio: considerations and diagnostic performance for malignant pleural effusion
Objectives: The objectives of this study included assessing the diagnostic performance of HE4 in malignant pleural effusions (MPEs) and identifying the benign etiologies associated with higher HE4 concentrations. Methods: The study involved patients with pleural effusion (PE) treated at Part Taulí University Hospital. PE and serum samples were collected and analyzed. Diagnosis of MPE was established by the presence of a positive cytology and/or positive pleural biopsy. HE4 concentrations in LP and serum – among other parameters – were measured on an ECLIA-Cobas e801 (Roche Diagnostics) analyzer. Subsequently, pleural fluid to serum HE4 ratio (PF/serum HE4 ratio) was calculated. Patients were assigned to different groups according to final diagnosis, transudate vs. exudate, MPE etiology and estimated glomerular filtration rate (eGFR). An evaluation was performed of the diagnostic performance of HE4 for MPE. Results: A total of 253 PF and serum samples were included. In patients with benign pleural effusion (BPE), transudates contained higher levels of HE4, as compared to exudates. The highest PF-HE4 concentrations and ratios were observed in MPEs, especially in patients with non-small cell lung cancer + ovarian cancer. The cut-off values established showed a sensitivity of 16.7 % (PF-HE4) and 12.1 % (ratio), with a 100 % specificity, respectively. Following cut-off adjustment, higher sensitivity values were observed in patients with an eGFR ≥ 30 mL/min/1.73 m 2 . Conclusions: Elevated HE4 concentrations may support MPE diagnosis and predict histology. Transudates contain elevated levels of HE4 and lower PF/serum-HE4 ratios. In the investigation of solid neoplasms, different serum HE4 cut-off values should be used for patients with PE, heart failure, cirrhosis or renal insufficiency.
- 25 August 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (8) , e265443
Paraneoplastic acral vascular syndrome in a patient with non-small cell lung adenocarcinoma with KRAS G12A oncogenic mutation
Paraneoplastic acral vascular syndrome (PAVS) is a rare condition characterised by signs of digital ischaemia, including Raynaud’s phenomenon, acrocyanosis and digital gangrene, in the context of an underlying neoplastic process. Prompt recognition of this syndrome, as well as accurate identification and classification of the associated neoplastic condition, are crucial. This report describes the case of a woman diagnosed with PAVS secondary to stage IV non-small cell lung adenocarcinoma harbouring a Kirsten Rat Sarcoma viral homolog oncogene (KRAS) G12A mutation (p.Gly12Ala).
- 25 August 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (8) , e265443
Paraneoplastic acral vascular syndrome in a patient with non-small cell lung adenocarcinoma with KRAS G12A oncogenic mutation
Paraneoplastic acral vascular syndrome (PAVS) is a rare condition characterised by signs of digital ischaemia, including Raynaud’s phenomenon, acrocyanosis and digital gangrene, in the context of an underlying neoplastic process. Prompt recognition of this syndrome, as well as accurate identification and classification of the associated neoplastic condition, are crucial. This report describes the case of a woman diagnosed with PAVS secondary to stage IV non-small cell lung adenocarcinoma harbouring a Kirsten Rat Sarcoma viral homolog oncogene (KRAS) G12A mutation (p.Gly12Ala).
- Open Access
Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy Response
Although immune checkpoint inhibitor (ICI) therapy is currently the standard of care in microsatellite-unstable (MSI) metastatic colorectal cancer (CRC), ICI therapy, alone or in combination with other therapies, is not a treatment approach in microsatellite-stable (MSS) CRC, which is present in 95% of patients. In this review, we focus on metabolic singularities—at the transcriptomic (either bulk or single cell), proteomic, and post-translational modification levels—that induce immunosuppression in cancer and specifically in MSS CRC. First, we evaluate the current efficacy of ICIs in limited and metastatic disease in MSS CRC. Second, we discuss the latest findings on the potential biomarkers for evaluating ICI efficacy in MSS CRC using strict REMARK criteria. Third, we review the current evidence on metabolic patterns in CRC tumors and immune cell metabolism to advance our understanding of metabolic crosstalk and to pave the way for the development of combination strategies to enhance ICI efficacy.
Open AccessMetabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy Response
Although immune checkpoint inhibitor (ICI) therapy is currently the standard of care in microsatellite-unstable (MSI) metastatic colorectal cancer (CRC), ICI therapy, alone or in combination with other therapies, is not a treatment approach in microsatellite-stable (MSS) CRC, which is present in 95% of patients. In this review, we focus on metabolic singularities—at the transcriptomic (either bulk or single cell), proteomic, and post-translational modification levels—that induce immunosuppression in cancer and specifically in MSS CRC. First, we evaluate the current efficacy of ICIs in limited and metastatic disease in MSS CRC. Second, we discuss the latest findings on the potential biomarkers for evaluating ICI efficacy in MSS CRC using strict REMARK criteria. Third, we review the current evidence on metabolic patterns in CRC tumors and immune cell metabolism to advance our understanding of metabolic crosstalk and to pave the way for the development of combination strategies to enhance ICI efficacy.
- 21 January 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 136, 110888
Utility of the combination of high fluorescence cells and tumor markers for the diagnosis of malignant pleural effusions
- 21 January 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 136, 110888
Utility of the combination of high fluorescence cells and tumor markers for the diagnosis of malignant pleural effusions